Answers are grounded in this paper and cite their sources.
BACKGROUND: The standard artemether-lumefantrine regimen for uncomplicated Plasmodium falciparum malaria comprises six doses over three days. Reports of late recurrence in non-endemic settings have prompted recommendations for longer regimens despite limited direct comparative evidence. We described early parasite clearance and 42-day recurrence after 3-day therapy in a selected cohort of adults without a documented previous malaria episode. METHODS: We conducted a retrospective single-centre cohort study of adults with imported uncomplicated P. falciparum malaria, no documented history of previous malaria, and initial treatment with oral artemether-lumefantrine at Geneva University Hospitals between 2015 and 2025. The primary outcome was asexual parasitaemia at 72 ± 8 hours. Secondary outcomes included parasite-clearance time, parasitological recurrence within 42 days, hospitalisation, intensive care unit admission, and mortality. RESULTS: Fifty-three patients were included. Median baseline parasitaemia was 0.2% (IQR, 0.05-0.5; range, 0.001-7.5). At 72 ± 8 hours, 51 of 52 evaluable patients had cleared parasitaemia (98.1%; 95% CI, 89.9-99.7), whereas one remained parasitaemic (1.9%; 95% CI, 0.3-10.1). Median parasite-clearance time was two days (IQR, 2-3). Day 2 was the most frequent clearance day, accounting for 24 of 53 patients (45.3%), and 36 of 53 (67.9%) had cleared by the end of day 2. Recurrence within 42 days occurred in 2 of 49 evaluable patients (4.1%; 95% CI, 1.1-13.7). No intensive care admissions or deaths occurred. CONCLUSIONS: In this selected cohort of non-immune adults with imported uncomplicated P. falciparum malaria, standard 3-day artemether-lumefantrine achieved rapid parasite clearance, with only one day-3-positive patient and two documented late recurrences. These findings provide clinically relevant real-world evidence supporting the continued evaluation of the standard regimen and question whether its routine upfront extension to 5 days is warranted for all non-immune patients.
No takes yet. Share an insight, caveat, or question.
Musumeci et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: